Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Amr Barakat

Cardiovascular Disease Jacksonville, FL Medical Doctor

NPI 1508270448 CMS profile 5705548

1824 King St Ste 300, Jacksonville, FL 32204

Open in the dashboard

General payments

$43,332

129 records reported · program years 2019–2025

Research payments

$5,000

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Amr Barakat of Jacksonville, FL is reported in the CMS Open Payments database as having received $43,332 across 129 general payments and $5,000 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $8,500 41
2025 Research $5,000 1
2024 General $1,877 21
2023 General $2,759 24
2022 General $1,821 23
2021 General $9,004 5
2020 General $17,833 3
2019 General $1,538 12

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Amr Barakat
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Amr Barakat were reported at $8,500. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Amr Barakat Cardiovascular Disease median Middle half National median
2019 $1,538 $450 $127–$1,392 $163
2020 $17,833 $242 $77–$751 $114
2021 $9,004 $335 $101–$1,037 $132
2022 $1,821 $395 $121–$1,211 $149
2023 $2,759 $443 $136–$1,283 $160
2024 $1,877 $450 $136–$1,323 $164
2025 $8,500 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $16,634 42 payments
  2. Medtronic Vascular, Inc. $9,659 11 payments
  3. Boston Scientific Corporation $9,429 23 payments
  4. Medtronic, Inc. $6,037 14 payments
  5. Biosense Webster, Inc. $336 10 payments
  6. Cardiva Medical, Inc. $259 9 payments
  7. CardioFocus, Inc. $239 2 payments
  8. Philips Electronics North America Corporation $183 4 payments
  9. HeartFlow, Inc. $157 2 payments
  10. Aziyo Biologics, Inc. $110 4 payments
  11. Other $289 8 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Grant $26,583 5 payments
  2. Travel and Lodging $6,611 23 payments
  3. Consulting Fee $5,775 1 payment
  4. Food and Beverage $4,042 98 payments
  5. Education $321 2 payments
Products named General payments · program years 2019–2025
  1. TACTICATH ABLATION CATHETER, SENSOR ENABLED $6,750 5 payments
  2. GENERAL - BRADY $5,000 1 payment
  3. EMBLEM S ICD ELECTRODE DELIVERY SYSTEM $3,750 1 payment
  4. AMPLATZER AMULET $2,073 8 payments
  5. AVEIR $1,262 7 payments
  6. ENSITE PRECISION $1,221 10 payments
  7. EVERA MRI XT DR SURESCAN $638 6 payments
  8. Heartlight System $239 2 payments
  9. Cardiva VASCADE MVP VVCS 6-12F $234 7 payments
  10. WATCHMAN Access System $222 2 payments
  11. Other $2,442 64 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Vektor Medical Inc. $5,000 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 17 drugs

Part D claims

757

Median for Cardiology: 2,533

Drug cost

$325,893

Median for Cardiology: $485,213

Branded share of claims

50.1%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 235 $219,211
Entresto Sacubitril/Valsartan Brand 31 $45,841
Xarelto Rivaroxaban Brand 41 $42,506
Multaq Dronedarone Hcl Brand 15 $11,150
Pradaxa Dabigatran Etexilate Mesylate Brand 12 $2,402
Flecainide Acetate Generic 34 $1,285
Metoprolol Succinate Generic 98 $1,224
Amiodarone Hcl Generic 90 $1,042
Pantoprazole Sodium Generic 54 $288
Sotalol Sotalol Hcl Brand 15 $245

The 10 drugs with the highest cost, of 17 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 71 billing codes

Paid by Medicare

$222,784

Medicare's payments for the services billed

Medicare patients

543

Average age 77

Services billed

2,815

277 women, 266 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Atrial fibrillation 73%
Ischemic heart disease 59%
Arthritis 55%
Heart failure 46%
Diabetes 44%
Chronic kidney disease 35%
COPD 29%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

130 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record